In pivotal lupus trials, BENLYSTA demonstrated significant disease activity reduction (SRI-4) at Week 523-5

SEE DATA

Reduction in risk of organ damage progression

SEE DATA

Reduction in rate of organ damage progression

SEE DATA

In a real-world, post hoc, propensity score-matched analysis.
Results are descriptive. See study design for data limitations.

 

REDUCTION OF ORGAN DAMAGE PROGRESSION6

The impact of BENLYSTA was evaluated in a real-world analysis
of organ damage progression.

Reduction of organ damage progression based on mean change in organ damage (SDI) from baseline to
Year 5* (primary endpoint)

Mean change in organ damage (SDI) from baseline to Year 5

Mean change in organ damage (SDI) from baseline to Year 5 chart

Organ damage progression was

less

than half

of ST alone

In a real-world, post hoc, propensity score-matched analysis.
Results are descriptive. See study design for data limitations.

* Includes all patients with ≥5 years of
follow-up.

SDI = SLICC/ACR Damage Index; ST = standard therapy; TLC = Toronto Lupus Cohort.

REDUCTION IN RATE OF ORGAN DAMAGE PROGRESSION6

Patients on BENLYSTA were

61%

less likely to progress to a higher organ damage score (SDI)*

(HR=0.39; 95% CI: 0.25, 0.61)

Annual probability of progression is based on
the increase in SDI score
per year (secondary endpoint)

Annual probability
of progression

Annual probability of progression chart

Patients on BENLYSTA were

61%

less likely to progress
to a higher organ
damage score (SDI)*

(HR=0.39; 95% CI: 0.25, 0.61)

In a real-world, post hoc, propensity score-matched analysis.
Results are descriptive. See study design for data limitations.

* Based on SDI score increases per year in patients with ≥1 year follow-up.

CI = confidence interval; HR = hazard ratio; SDI = SLICC/ACR Damage Index; ST = standard therapy.

Expand all       Collapse all

WHAT WAS THE STUDY DESIGN?

  • STUDY DESIGN6

    A post hoc, PSM comparative analysis was performed to assess the difference
    in organ damage (SDI) progression between patients in BLISS-76 LTE* and
    from the TLC.†

    Post hoc PSM study design

    KEY LIMITATIONS OF THIS PSM STUDY6

    • Post hoc analysis
    • Patients matched based on known variables only
    • Patients could not be matched by year of entry into the study
    • Differences in patient populations

    * To be eligible, patients on BENLYSTA had to be in the United States; regimen was BENLYSTA IV 10 mg/kg + ST.

    † Chosen based on its size, the extent of organ damage in patients, and the severity of disease activity. Regimen was
    ST alone.

    LTE = long-term extension; PSM = propensity score matching; SDI = SLICC/ACR Damage Index; ST = standard therapy;
    TLC = Toronto Lupus Cohort.

  • WHAT PATIENT CHARACTERISTICS WERE USED IN THE PSM ANALYSIS?

    PSM: A method to match
    and compare patients
    from different studies6

    Patients are matched based on propensity scores calculated using the 17 predictors of organ damage listed below:

    Table: Patient characteristics in the PSM analysis

    Once matched, any observed differences between patients are presumed to be a
    result of the treatment    .

    ACR = American College of Rheumatology;
    PSM = propensity score matching; SDI =
    SLICC/ACR Damage Index; SLE =
    systemic
    lupus erythematosus; SLEDAI = SLE Disease Activity Index.

 

DID YOU KNOW?

Icon: Patient silhouette

APPROXIMATELY 1 IN 2 PATIENTS EXPERIENCE IRREVERSIBLE ORGAN DAMAGE WITHIN 5 YEARS OF DIAGNOSIS1,2*†

Organ damage in patients with lupus can affect multiple organ systems1,7,8

Icon: Musculoskeletal

Musculoskeletal

Icon: Pulmonary

Pulmonary

Icon: Renal

Renal

Icon: Cardiovascular

Cardiovascular

Icon: Ocular

Ocular

Icon: Ocular

Ocular

List of organ systems is not all inclusive.

* Damage in SLE is defined as an irreversible tissue injury occurring after diagnosis of SLE and lasting at least 6 months.
SLICC/ACR Damage Index (SDI) is the internationally agreed and validated measure of organ damage.8,9

† Cohort analysis of 298 patients followed for a minimum of 5 years by the SLICC International Research Network, comprising 27 centers from 11 countries. Year 0 represents time of enrollment. Mean age at enrollment was 35.3 years. Fifty percent of patients acquired organ damage at Year 5.2 Retrospective analysis of records from 401 patients (232 patients with ≥10 years of consistent follow-up) attending the University College London Hospital SLE clinic between 1978-2004. Year 0 represents time of diagnosis. Mean age at diagnosis was 31.2 years. Thirty-three percent of patients acquired organ damage at Year 5.1

SLE = systemic lupus erythematosus; SLICC/ACR = Systemic Lupus International Collaborating Clinics/American College of Rheumatology.

Lupus Patient: Valerie

Hear the story of a patient experiencing organ damage*

MEET VALERIE

* Hypothetical patient profile.

LEARN MORE

Efficacy for lupus BENLYSTA improves key clinical
outcomes in patients with lupus.

Safety profile Well-established safety based on the
largest clinical trial program in lupus and
lupus nephritis.

What could slowing the progression of organ damage mean for your patients?

BENLYSTA Patient
BENLYSTA Patient